Diligence memo · auto-generated · as of July 2, 2026
OptiNose, Inc.
OptiNose, Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
OptiNose, Inc. operates in Pharmaceuticals, based in Yardley.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
OptiNose, Inc. has raised $120M in disclosed capital across 8 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $35M on 2017-03-24.
Most recent recorded round closed around 2024-05-10.
Valuation (modeled)modeled
Provath models OptiNose, Inc. at approximately $35M (range $9.8M–$64M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.27× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 21 months.
Last raise 2.1 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 1.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 93% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.